Clinical Trial Update: Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites [Phase 4]

View source ↗

Summary

Phase 4 trial update on Samsca (tolvaptan) regarding control of hyponatremia and extracellular fluid in cirrhosis with ascites; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis

Drugs mentioned

• Samsca (tolvaptan)

Snippet

Sponsor: Korea Otsuka Pharmaceutical Co., Ltd. | Conditions: Hyponatremia and Extracellular Fluid in Cirrhotic | Phase 4 | Status: TERMINATED